Updated from 8:49 a.m. EDT
shares rose Monday after the company said it had won regulatory approval for a generic version of
hypertension drug Lopressor.
The Pittsburg-based generic drugmaker said the Food and Drug Administration has approved its metoprolol tartrate and hydrochlorothiazide tablets, which will compete with the Lopressor HCT tablets made by the Switzerland-based Novartis.
Mylan also announced it has received tentative FDA for its cetirizine hydrochloride tablets and sertraline hydrochloride tablets, which are respective generic versions of the
drugs Zyrtec, used to treat allergies, and Zoloft, a medication for depression and other disorders.
In late July, Mylan said it had agreed to merge with
in a stock-swap deal valued at $4 a share at the time.
Shares added 36 cents, or 2.1%, to $17.25.